Wednesday, October 31, 2018

PotNetwork Holdings, Inc. Announces Diamond CBD to Pursue FDA Product Registrations

Diamond CBD Developing Products To Be IP-Protected for Unique Niche Markets Applications


FORT LAUDERDALE, Fla. -Wednesday 31 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- PotNetwork Holdings, Inc. (OTC Pink: POTN)(the “Company”) announced today that, as the U.S. CBD market grows and expands, the Company is aggressively developing new products and moving forward on its strategy of exploring and initiating FDA registrations, patents and trademarks specific to certain of its new proprietary, Diamond CBD products.

The Company had previously announced that it had engaged major law firms in Fort Lauderdale, Florida, and Washington, D.C., to handle intellectual property (“IP”) matters, and for regulatory guidance on FDA submissions and related matters pertaining to the evaluation of the feasibility of FDA approval and registrations for certain Diamond CBD formulations.

Kevin Hagen, CEO, stated, “We believe that the future success of our Company is linked to carving out proprietary niche markets specific to unique, product formulations. Today, we are pushing forward with this strategy specific to human health and wellbeing issues under the guidance of our Scientific Advisory Board, who will oversee preliminary patient clinical trials in accordance with FDA guidelines and procedures. Our goal is to establish a unique company positioning in key markets with this initiative.” He added, “We are fortunate to be working with both talented doctors, scientists and legal advisors, who can help us achieve this goal. We believe that this strategy will further benefit the building of overall shareholder value.”

About Diamond CBD, Inc.: Diamond CBD focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD’s team consists of hemp industry pioneers and natural product experts, chemists, doctors and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a robust selection considered among the most powerful natural CBD oils, tinctures, edibles, and vape liquids found anywhere. For more information, please visit its website at www.DiamondCBD.com.

About PotNetwork Holdings, Inc.: PotNetwork Holdings, Inc. (OTC Pink: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils.

Safe Harbor: This press release contains Forward-Looking Statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.



View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005407/en/




Contacts

PotNetwork Holdings, Inc.
Investor Relations:
Marisol Elwell, 1-800-915-3060
investor@PotNetworkHolding.com



Permalink : https://www.aetoswire.com/news/potnetwork-holdings-inc-announces-diamond-cbd-to-pursue-fda-product-registrations/en

Fraser Suites Top Glory, Shanghai Celebrates 10th Anniversary in Shanghai



SHANGHAI-Wednesday 31 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Fraser Suites Top Glory, Shanghai held a celebrating event in Shanghai for its 10th anniversary on October 28th and extended its gratitude to the guests and staff for their long-lasting support. The glamorous event was attended by 260 guests, staff, and company officials, including Mr. Choe Peng Sum, CEO of Frasers Hospitality and Mr. Huang Guiqin, Deputy Manager of Hotel Management Department, COFCO Land Limited.

Fraser Suites Top Glory, Shanghai has 185 2-bed and 3-bed luxury suites, measuring 211-360m2. Located in the bustling Lujiazui CBD financial district by the Huangpu River, the property gives the guests a spectacular view of the river and the Bund. Meanwhile, adjacent to landmarks like Shanghai Tower, Shanghai World Financial Center and Jinmao Tower where numerous Fortune 500 companies are gathered, the property is highly favored by business elites, including Fortune 500 CEOs.

At the event, Mrs. Chan, a long-stay guest of the property, recalled, “We’ve been living here since its opening and we loved it. We enjoyed its cross-cultural community where we were acquainted with friends from around the world. And the staff were always considerate and prepared to meet our daily needs.”

“Our long-stay guests stayed with us for 3.5 years on average, and over 80% of them are with their family. Our attraction lies not only in the advantaged location or wonderful facilities, but also in the extraordinary services provided by our professional staff, whom have made the property the second home of our guests,” said Madam Zhao Xuhong, CFO of COFCO Land Limited Shanghai and Mr. Choe Peng Sum, CEO of Frasers Hospitality.

Fraser Suites Top Glory, Shanghai has been living to its core values of “Collaboration, Recognize, Real & Respectful”, which has empowered its growth in the past decade. “I thank our guests and staff for staying with us, without whom our achievements could not have been possible. Let’s join hands as we look forward to the coming decade,” said Mr. Michael Tam, General Manager of Fraser Suites Top Glory, Shanghai.

About Frasers Hospitality

Frasers Hospitality is a global hospitality operator with properties across Australia, Southeast Asia, North Asia, Middle East, Africa, and Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181030005903/en/

Contacts

Fraser Suites Top Glory, Shanghai
Ms. Titi Zhuang
Director of Sales
titi.zhuang@fraserhospitality.com



Permalink : https://www.aetoswire.com/news/fraser-suites-top-glory-shanghai-celebrates-10thnbspanniversary-in-shanghai/en

Quanergy Completes Series C Financing with a Valuation Surpassing $2 Billion

Latest round will accelerate product innovation and mass production of revolutionary S3 solid-state LiDAR and keeps IPO process on track


SUNNYVALE, Calif.-Wednesday 31 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Quanergy Systems, Inc., a global leader in the development and manufacture of LiDAR sensors and smart sensing solutions, today announced it has secured Series C funding at a valuation exceeding $2 billion, with a global top-tier fund as the lead investor.

Raising the Series C financing takes the company well beyond its planning horizons to cash-flow and operating breakeven, and keeps the company’s IPO process on track.

Demand for Quanergy’s solutions continues to be strong, with revenue increasing rapidly and bookings exceeding forecast. Product and software development continues at a brisk pace. Substantial orders for the company’s S3 solid-state sensor were fulfilled this year. Rapid innovation continues to increase the field of view (FoV) and range for the S3 in outdoor environments.

Led by the world's most experienced and innovative LiDAR team, as evidenced by its seven granted and eight pending patents, Quanergy has pioneered the development of low-cost, high-quality compact solid-state LiDARs for a wide range of applications in autonomous vehicles, smart security, industrial automation, and 3D mapping. Since the end of 2017, Quanergy has had an annual production capacity of one million solid-state sensors at its fully automated production line in Silicon Valley. The completion of this round of financing will further enhance the company's capital reserve, to accelerate innovation and commercialization of its hardware, software and smart sensing solutions, and construction of ultra-large-scale production facilities.

Since the beginning of this year, Quanergy has been receiving numerous awards and certifications: Juniper Research's annual best consumer product award in Automotive and Telematics, Silicon Valley Chamber of Commerce’s annual award for Outstanding Innovation in LiDAR Sensing Technology, followed by ISO 9001:2015 certification, and IATF 16949 automotive production qualification for solid-state sensor production, a big step in the mass production of automotive-grade S3 LiDAR, the company’s flagship product.

"With our advanced technology, we have reduced the price of solid-state LiDAR to a few hundred dollars in volume,” said Dr. Louay Eldada, CEO of Quanergy. “Our third-generation solid-state LiDAR is being developed to fully integrate the sensor on a single chip. For Quanergy, the most important focus at the moment is to speed up the production ramping and prove our strength with mass-produced products."

About Quanergy Systems, Inc.

Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software, and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers smart sensing solutions. It is a leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D spatial data and object detection, identification, classification, and tracking. Its sensors are disruptive in price, performance, reliability, size, weight, and power. Its solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, smart spaces and 3D-aware smart devices for improved safety, efficiency and quality of life. For more information, visit www.quanergy.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181030005434/en/

Contacts

Quanergy Systems, Inc.
Ann Gargiulo
Sr. Director of Marketing Communications
+1-408-245-9500
media@quanergy.com

Permalink : https://www.aetoswire.com/news/quanergy-completes-series-c-financing-with-a-valuation-surpassing-2-billion/en

Presidents, Prime Ministers, and AI Sensation Sophia the Robot to Gather at the 12th Global Residence and Citizenship Conference in Dubai



LONDON-Wednesday 31 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- More than 400 delegates from over 40 countries are expected to attend the 12th annual Global Residence and Citizenship Conference, which takes place next week (4–6 November) in Dubai.

Hosted by leading international citizenship and residence advisory firm Henley & Partners, this annual event has become the world’s largest and most significant conference on investment migration, bringing together presidents, prime ministers, senior government ministers and officials, leading academics, experienced industry professionals, and top-tier financial and business media.

Dr. Christian H. Kalin, Group Chairman of Henley & Partners, says residence- and citizenship-by-investment programs are very much the new frontier in terms of freedom, flexibility, and future-readiness. “The societal and economic value they are able to generate is truly extraordinary, which is why we are seeing such strong industry growth year-on-year. The industry as a whole, with residence and citizenship combined, is currently grossing roughly USD 18 billion per year, and we expect that we will hit the USD 20 billion mark very soon.”

Headlining the conference will be artificial intelligence sensation Sophia, the world’s first-ever robot-citizen. Sophia will introduce an exclusive panel debate on the battle for digital supremacy being waged between the global superpowers and on what this new technological climate means for the future of global citizenship.

The Moldova Citizenship-by-Investment (MCBI) program — the latest and most exciting new investment migration opportunity in Europe — will be officially launched at the conference. Minister of Economy and Infrastructure for the Republic of Moldova H.E. Chiril Gaburici said, “The MCBI program will provide our economy with much-needed foreign direct investment that will enhance the daily lives of all Moldovans, while strict due diligence standards and compliance procedures will guarantee the credibility and sustainability of the program.”

Other notable key speakers include President of Montenegro, H.E. Milo Ðukanovic; the Hon. Dr. Timothy Harris, Prime Minister of St. Kitts and Nevis; and Peter S. Vincent, Assistant Director General for International Policy at BORDERPOL and General Counsel for Thomson Reuters. The event will be co-hosted by Tariq Qureishy, Founder and CEO of MadTalks, Dubai, and Katie Fielder, Dubai-based journalist and broadcaster.

The conference will conclude with a gala dinner during which the 2018 winner of the Global Citizen Award® will be announced. The award is presented each year to an inspiring individual who has made an extraordinary and courageous contribution to the global community.



View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005109/en/

Contacts

Media
Sarah Nicklin
Senior Group Public Relations Manager
sarah.nicklin@henleyglobal.com

Permalink : https://www.aetoswire.com/news/presidents-prime-ministers-and-ai-sensation-sophia-the-robot-to-gather-at-the-12th-global-residence-and-citizenship-conference-in-dubai/en

Western Union and Amazon to Launch New Way to Pay

Connecting cross-border shoppers to the vast reach of Western Union’s network


DENVER -Wednesday 31 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement, today announced it is has been engaged by Amazon to launch a new payment option that allows international shoppers to pay in person, in local currency where available, for their online purchases. Amazon is focused on providing international customers with access to millions of products.

Western Union’s money movement platform will power a new payment option for cross-border customers shopping on Amazon.com. Customers in select countries will be able to shop on Amazon and pay in person, in local currency, through the Western Union® agent network.

“There are people in the world who want greater access to Amazon’s huge product selection but paying for those purchases has been a real obstacle for many customers,” said Hikmet Ersek, president and CEO of Western Union. “We’re leveraging our money movement platform to make it easier to shop global and pay local. By facilitating the complex foreign exchange and settlement process, we’re opening up more consumer choices and access to online shopping for tens of millions of potential new Amazon customers.”

Expanding Customer Access and Closing the Payments Gap

Forrester Research estimates that cross-border shopping will make up 20% of e-commerce by 2022, with sales reaching $630 billion.1 Choice, quality and cost are the main motivations for consumers to shop online from overseas, but there are challenges and concerns about the lack of payment options for consumers who prefer to pay in person or consumers who are not comfortable using online payment methods.

Customers in select countries will be offered the new payment option on the Amazon checkout page. Shoppers will be sent a code and instructions on how to make the payment at a participating Western Union agent location. Western Union’s platform will also power the process for cash refunds for product returns.

About Western Union’s Cross-Border Platform

Western Union’s cross-border, cross-currency money movement platform – including a robust digital footprint, settlement, treasury and compliance infrastructure, a vast global retail network of over half a million locations, and the ability to send money to billions of accounts and mobile wallets – sets the standard for international money movement. With operations in more than 200 countries and territories, Western Union’s platform processed an average of 32 transactions every second and moved $300 billion in principal across 130 currencies in 2017.

Connecting the digital and physical worlds of money, Western Union’s technology stack, APIs, foreign exchange and settlement engine, agent network, anti-money laundering and fraud detection capabilities make it one of the largest digital and physical money movers for consumers around the globe. The company offers digital transactions in more than 50 countries and territories. Approximately 70% of Western Union’s digital transactions globally now originate on mobile devices.

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

1Source: Forrester Research, “Online Cross-Border Retail Forecast, 2017-2022 (Global),” April 20, 2017

WU-G





View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005237/en/

Contacts

Media contacts
Western Union
John Derryberry
+1 415-203-8762
john.derryberry@wu.com
or
Fleishman Hillard
Katie Elkington
+1 917-701-6477
katie.elkington@fleishman.com

Permalink : https://www.aetoswire.com/news/western-union-and-amazon-to-launch-new-way-to-pay/en

Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer

• Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities, effective December 31, 2018

• Per Falk will be the next President of the Executive Committee and Chief Science Officer, effective January 1, 2019



SAINT-PREX, Switzerland-Wednesday 31 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Per Falk, Chief Science Officer, will assume additional responsibility as President of the Executive Committee, effective January 1, 2019.

Michel has had an exceptional career at Ferring, taking the company from revenues of €345 million when he joined the company in 2001 to nearly €2 billion today. In addition, Ferring is now in the Top 50 Global Pharma Companies 2018.

“I would like to express my sincere appreciation for Michel’s commitment to Ferring, his considerable achievements and his passion for supporting patients and helping people live better lives,” said Frederik Paulsen, Chairman of the Ferring Board of Directors. “I wish Per every success in his expanded leadership role. With his strong scientific and medical background, Per will lead Ferring with the Executive Committee to its next phase of growth and innovation.”

Per joined Ferring in 2015 and has been instrumental in leading and driving change for R&D and the wider organisation, while ensuring that the business can realise its full potential in the future. In addition, Per has accelerated Ferring’s focus on the microbiome through a number of external collaborations and the recent acquisition of Rebiotix. Prior to joining Ferring, Per worked at Novo Nordisk for 12 years and served in several executive and leadership roles, including R&D and regional commercial leadership teams. Per is a qualified medical doctor and also has a PhD in Biochemistry and Clinical Chemistry.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

Contacts

Ferring Pharmaceuticals
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
or
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

https://www.aetoswire.com/news/ferring-announces-retirement-of-michel-pettigrew-president-of-the-executive-board-and-chief-operating-officer/en

NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform

TOKYO, Japan & STRASBOURG, France -Tuesday 30 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- NEC Corporation (NEC)(TOKYO:6701) and Transgene (Euronext Paris:TNG) today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC’s artificial intelligence (AI) and the therapeutic potential of Transgene’s myvac™ MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimental products from this collaboration are expected to enter clinical trials in 2019.

NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.

Immunotherapy is rapidly becoming the treatment of choice to fight cancer as it activates the patient’s own immune system to attack cancer cells.

NEC and Transgene have capitalized on the recent progress in AI and advances in genome sequencing to create individualized immunotherapy, which is adapted to the unique characteristics of each patient’s mutational landscape as well as their predicted immune responses. The product is based on a viral vector (MVA) developed by Transgene with a proven clinical safety track record and is known for its efficient immunogenicity and anti-tumor efficacy in patients.

The viral vector will be used to target neoantigens identified using NEC’s proprietary algorithm. NEC has been developing solutions in the drug discovery field for close to two decades. NEC’s neoantigen prediction system was developed and validated based on publicly available databases, as well as internal wet lab datasets, some of which were already used to identify clinically relevant antigens in other oncology indications.

These planned clinical trials leverage the world-leading expertise and technologies of a network of companies and research centers, including:

    NEC’s cutting-edge AI technology, “NEC the WISE”, for identifying and prioritizing patient-specific neoantigens, and
    Transgene’s unrivaled MVA-based, viral vector technology and the myvac™ platform.

“The emerging personalized medicine field holds great potential for the application of NEC’s core technology, and we are pleased to be working with Transgene with the goal of developing state-of-the-art personalized immunotherapies,” said Motoo Nishihara, Senior Vice President, Head of NEC Laboratories.

“Engaging the body’s own immune system in the fight against cancer has shown great promise and sparked unprecedented interest among oncology drug makers. This makes it imperative for NEC to become part of the immunotherapy race as soon as possible,” said Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation.

“This collaboration brings together artificial intelligence and our expertise in viral vector engineering to enable the development of a truly innovative treatment based on the myvac™ platform. We believe that our collaboration with NEC will allow us to provide an efficacious and robust therapy for the many patients who have solid tumors and could benefit from this cutting-edge individualized approach, and to successfully advance the development of the myvac™ platform to the market” said Éric Quéméneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.





View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005305/en/

Contacts

NEC Corporation
Joseph Jasper, +81-3-3798-6511
j-jasper(at)ax.jp.nec.com

Permalink : https://www.aetoswire.com/news/nec-and-transgene-announce-a-collaboration-in-the-field-of-individualized-cancer-immunotherapy-leveraging-nec39s-ai-and-transgenersquos-myvactrade-platform/en

Tuesday, October 30, 2018

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1

 New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults with HIV-1 when treated with D/C/F/TAF1



GLASGOW, Scotland-Tuesday 30 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- The Janssen Pharmaceutical Companies of Johnson & Johnson today unveiled 96-week results from the pivotal Phase 3 AMBER study of SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF)) at HIV Glasgow in Scotland. D/C/F/TAF is a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg. Genotypic testing should guide the use of D/C/F/TAF.2

Results from the AMBER study demonstrated that a high proportion of antiretroviral treatment (ART)-naïve adults with HIV-1 (85%, 308/362) maintained virologic suppression (viral load <50c/mL; FDA-snapshot) at 96 weeks when treated with D/C/F/TAF. No darunavir, primary protease inhibitor, or tenofovir resistance-associated mutations emerged in any patient. As previously reported, only one patient receiving D/C/F/TAF developed a nucleoside reverse transcriptase inhibitor resistance-associated mutation (M184V) through week 48. In the current analysis through 96 weeks, only one additional patient receiving D/C/F/TAF developed a nucleoside reverse transcriptase inhibitor resistance-associated mutation to emtricitabine (M184V).1

These 96-week data, which follow on from the earlier 48-week results,3 reinforce the long-term efficacy, high genetic barrier and safety of D/C/F/TAF as a treatment for ART-naïve adults with HIV-1.1 The control arm of the study consisted of 512 patient years exposure to darunavir (D)+ cobicistat (C)+ emtricitabine (F)/ tenofovir disoproxil fumarate (TDF) and 109 patient years exposure to D/C/F/TAF.1

“The 96-week results from the AMBER study demonstrate that the darunavir-based single-tablet regimen has a good safety profile and efficacy and a high genetic barrier beyond the first year of treatment. The regimen adds to the choices for patients who start and receive life-long HIV therapy,” said Professor Chloe Orkin, Lead for HIV research at Barts Health NHS Trust.

D/C/F/TAF was generally well-tolerated with 3% (10/362) adverse event (AE)-related discontinuations over 96 weeks and 3% (11/362) of people experiencing a grade 3 or 4 study-drug related AE, compared with 1% (3/295) in the comparator arm. Bone, renal and lipid safety were consistent with known tenofovir alafenamide and cobicistat profiles.1 Efficacy and safety results were consistent with the 48-week results in the D/C/F/TAF group.1

“These results mark another important milestone in ensuring that individualised treatment options are available to those living with HIV-1,” said Kimberley Brown, PharmD, AAHIVE, Study Responsible Scientist, Janssen Research & Development, LLC. “At Janssen, we are building on our 25-year heritage in HIV and remain committed to ongoing research and development of innovative solutions with the aim to make HIV history.”

On September 26, 2017, D/C/F/TAF was approved for the treatment of HIV-1 infection by the European Commission,4 based on results from a bioequivalence study that compared D/C/F/TAF with the combined administration of the separate agents darunavir [D] 800 mg, cobicistat [C] 150 mg, and emtricitabine/tenofovir alafenamide [FTC/TAF] 200 mg/10 mg fixed-dose combination.5 US FDA approval was granted on July 17, 20186 based on the results from the two pivotal Phase 3 studies, EMERALD and AMBER.3,7

96-week results from the Phase 3 EMERALD trial in treatment-experienced virologically suppressed adults with HIV-1 were recently presented at IDWeek 2018, in San Francisco, CA.8

D/C/F/TAF does not cure or prevent HIV-1 or AIDS.

Notes to editors

About the AMBER clinical trial1,3

AMBER is a Phase 3 randomised, double-blind, active-controlled, international, multi-centre, non-inferiority study designed to assess the safety and efficacy of D/C/F/TAF versus the control in HIV-1 treatment-naïve patients at Week 48, and the long-term efficacy and safety of D/C/F/TAF at Week 96. The control was comprised of two separate medications – darunavir/cobicistat plus emtricitabine 200mg/tenofovir disoproxil fumarate 300mg – and patients were randomly assigned (362 D/C/F/TAF; 363 control). Based on the results of the primary analysis all patients, after unblinding, received treatment with D/C/F/TAF during an open-label single group treatment phased up to Week 96. The primary endpoint was non-inferiority of the single-tablet regimen versus the control regarding the proportion of patients that achieved viral suppression (viral load of less than 50 c/mL at 48 weeks – per FDA snapshot analysis). Reaching suppression of viral load (or the amount of HIV virus in the blood) is a key treatment goal for people living with HIV-1. FDA snapshot efficacy outcomes were also reported.1

48-week data have been previously reported.3 At Week 96, of the 725 patients treated, a high proportion of patients in the D/C/F/TAF arm (85%, 308/362) maintained virologic suppression (viral load of <50c/mL – per FDA Snapshot analysis), compared to 88% (321/363) in the comparator arm. Viral load of ≥50c/mL per the FDA Snapshot at Week 96 occurred in 20/362 (6%) patients in the D/C/F/TAF arm, compared to 3% (12/363) in the control arm. No darunavir, primary protease inhibitor, or tenofovir resistance-associations emerged in any patient. Through 96 weeks, only two patients receiving D/C/F/TAF developed a nucleoside reverse transcriptase inhibitor resistance-associated mutation to emtricitabine (M184V).1 D/C/F/TAF was generally well-tolerated with few serious adverse events. 11% (39/362) of patients experienced serious adverse events and 3% (10/362) experienced adverse event-related discontinuations. No deaths occurred. In the comparator arm, 3% (8/295) of patients experienced serious adverse events and 1% (<1/295) experienced adverse event-related discontinuations. Bone, renal and lipid safety were consistent with known tenofovir and cobicistat profiles, with a small change in TC/HDL-C ratio.1 Efficacy and safety results were consistent with the 48-week results seen in the D/C/F/TAF arm.1

Cobicistat, emtricitabine and tenofovir alafenamide are from Gilead Sciences, Inc. On December 23, 2014, Janssen and Gilead Sciences Inc. amended a licensing agreement for the development and commercialisation of a once-daily single-tablet regimen combination of darunavir and Gilead's TAF, emtricitabine and cobicistat. Under the terms of the agreement, Janssen and its affiliates are responsible for the manufacturing, registration, distribution and commercialisation of this single-tablet regimen worldwide.

About D/C/F/TAF2

In the European Union, D/C/F/TAF is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of D/C/F/TAF.2

D/C/F/TAF is a fixed-dose combination of four active substances (darunavir, cobicistat, emtricitabine and tenofovir alafenamide), available as 800 mg/150 mg/200 mg/10 mg film-coated tablets. Darunavir inhibits the HIV protease and prevents the formation of mature infectious virus particles. Emtricitabine and tenofovir alafenamide are substrates and competitive inhibitors of HIV reverse transcriptase. After phosphorylation, they are incorporated into the viral DNA chain, resulting in chain termination. Cobicistat enhances the systemic exposure of darunavir and has no direct antiviral effect.2

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea and follow us at @JanssenEMEA. Janssen-Cilag International NV and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Prescribing and safety information

For important prescribing and safety information for D/C/F/TAF in the European Union please visit: www.ema.europa.eu/en/medicines/human/EPAR/symtuza

For complete prescribing and safety information in the UK, please visit: www.medicines.org.uk/emc/product/8430

▼Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447 or at dsafety@its.jnj.com.

References

1 Orkin C, Eron JJ, Rockstroh J, et al. Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in antiretroviral treatment (ART)-naïve, HIV-1-infected adults: AMBER Week 96 results. Presented at HIV Glasgow 2018, Glasgow, October 28-31,; abstract O212. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25187. Last accessed October 2018.

2 Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets. Summary of product characteristics. Janssen-Cilag Ltd. Last updated 27 Sept 2018. Available at: www.medicines.org.uk/emc/product/8430/smpc Last accessed October 2018

3 Gallant J, et al. Week 48 results of AMBER: a phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/ tenofovir disoproxil fumarate (FTC/TDF). Presented at the European AIDS Clinical Society Conference 2017. Milan, October 25-27, 2017; abstract PS8/2. Available at: www.abstractserver.com/eacsabstractarchive/ Last accessed October 2018.

4 Janssen. European Commission approves Symtuza® for the treatment of HIV-1 in adults and adolescents in Europe. Press release 26 September 2017. Available at: www.jnj.com/media-center/press-releases/european-commission-approves-symtuza-for-the-treatment-of-hiv-1-in-adults-and-adolescents-in-europe Last accessed October 2018.

5 Crauwels H, et al. Bioequivalence of a darunavir-based single-tablet complete HIV-1 regimen compared to the separate agents. Presented at 9th IAS Conference on HIV Science 2017; abstract MOPEB0335. Available at: http://programme.ias2017.org/Abstract/Print/?abstractid=4016 Last accessed: October 2018.

6 Janssen. Janssen announces U.S. FDA approval of SYMTUZA (D/C/F/TAF), the first and only complete darunavir-based single-tablet regimen for the treatment of HIV-1 infection. Press release July 17, 2018. Available at: www.janssen.com/janssen-announces-us-fda-approval-symtuza-dcftaf-first-and-only-complete-darunavir-based-single-0 Last accessed October 2018.

7 Molina JM, et al. Efficacy and safety of switching from boosted-protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults through 24 weeks: EMERALD study. Presented at 9th IAS Conference on HIV Science 2017; abstract TUAB0101. Available at: http://programme.ias2017.org/Abstract/Abstract/4194 Last accessed: October 2018.

8 Eron J, et al. Efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine/tenofovir disoproxil fumarate (F/TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults: week 96 results of the phase 3, randomized, non-inferiority EMERALD trial. Presented at IDWeek 2018, San Francisco, CA, USA, October 3-7, 2018; abstract 1768. Available at: https://idsa.confex.com/idsa/2018/webprogram/Paper72755.html Last accessed October 2018.



View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005577/en/

Contacts

Media Enquiries:
Inès Hammer
Phone: +33 688 093 335
or
Investor Relations:
Lesley Fishman
Phone: +1 732-524-3922
or
Christopher DelOrefice
Phone: +1 732-524-2955


Permalink : https://www.aetoswire.com/news/janssen-presents-positive-long-term-efficacy-and-safety-of-symtuzareg-d-c-f-taf-in-treatment-naiumlve-adults-with-hiv-1/en

Nordson EFD Introduces Dial-A-Dose and Posi-Dose Animal Health Dosing Syringes

EFD provides advanced primary packaging and controlled drug delivery systems for animal health products worldwide.



EAST PROVIDENCE, R.I. -Tuesday 30 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Nordson EFD, a Nordson company (NASDAQ: NDSN) and the world’s leading precision fluid dispensing systems manufacturer, announces its entry into a new market with the introduction of a comprehensive line of disposable dosing syringes for animal health products such as veterinary pharmaceuticals and nutritional supplements.

EFD leverages more than 50 years of experience in precision molding processes for its industrial fluid dispensing components to deliver high-quality, advanced primary packaging and controlled drug delivery syringes to the global animal health market.

Its industry-leading Dial-A-Dose™ syringes provide an innovative solution for end users to customize multiple doses for an animal based on the product manufacturer’s specified treatment calibrations such as milliliters, cubic centimeters, the animal’s weight, etc. An integrated ring allows users to “dial in” and administer the correct dose. Nozzle caps allow users to securely reseal the syringe until its next use.

EFD’s Posi-Dose® syringe, designed for equine oral deworming treatments, features a unique twist-lock ring that snaps into position to set specific dosing volumes. Its nozzle-free design ensures positive confirmation that every dose is completely administered. It too can be re-sealed for multi-dose use.

In addition, Nordson EFD offers a wide variety of dosing syringe sizes (6cc to 100cc volumes) and nozzle types for oral, topical, and intramammary uses. One-piece and two-piece plungers without “dialing” mechanisms are also available.

“Our comprehensive line of animal health dosing syringes can be used in a variety of bovine, equine, and companion animal treatments,” said Mark O’Shea, Global Product Line Specialist at Nordson EFD. “All of them are molded from 100% FDA-approved resins. Most feature a unique 'lead-in' aid that accommodates high-speed filling by simplifying the plunger insertion process. And some feature an innovative, self-venting feature that prevents air entrapment for accurate, reliable dosing.”

Custom stamping marks, colors, syringe sizes, and product designs are possible. Customers can also request in-mold labeling or standard labeling for their EFD dosing syringes.

Learn more about EFD’s disposable animal health dosing solutions by downloading this application guide, watching this video, or requesting samples.

For more information, visit Nordson EFD on the web at nordsonefd.com/animalhealth, facebook.com/NordsonEFD, or linkedin.com/company/nordson-efd, email at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.

About Nordson EFD

Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.

About Nordson Corporation

Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.



View this news release online at:
http://www.businesswire.com/news/home/20181030005008/en

Contacts

Nordson EFD
Natalie Tomasso, +1-401-431-7173 (USA)
Marketing Communications Specialist
natalie.tomasso@nordsonefd.com
or
Nordson EFD
Global
Natalie Tomasso, +1-401-431-7173
natalie.tomasso@nordsonefd.com
or
Europe
+44 (0) 1582 666334
europe@nordsonefd.com
or
China
+86 (21) 3866 9006
china@nordsonefd.com
or
Japan
+81 (03) 5762 2760
japan@nordsonefd.com
or
SEAsia
+65 6796 9522
sin-mal@nordsonefd.com
or
India
+91 80 4021 3600
india@nordsonefd.com


EASA Approves AerTrak ADS-B Out System for Boeing 737 NG Series Aircraft

CORAL GABLES, Fla.-Thursday 25 October 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- AerSale®, a global supplier of mid-life aircraft, engines, used serviceable material, and MRO services, announced today that the European Aviation Safety Agency (EASA) has approved the company’s AerTrak™ ADS-B Out system on Boeing 737 NG series aircraft (10065422). Earlier this year, the Federal Aviation Administration (FAA) approved AerTrak for Boeing 737 NG series aircraft (ST04009NY) and Boeing 757-200 series aircraft (ST04011NY) to comply with the FAA’s Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule. The Boeing 757-200 series aircraft Supplemental Type Certificate (STC) is now pending EASA and National Civil Aviation Agency of Brazil (ANAC) validation.

“With this validation, we demonstrate our commitment to our European customer base,” said Iso Nezaj, Chief Technical Officer at AerSale. “Operators can now choose a fully-compliant ADS-B Out system visible to all—with no certification fees. We’re working to expand AerTrak to cover additional aircraft types and look forward to making those announcements in the coming months.”

ADS-B provides enhanced navigational accuracy using precise tracking via global positioning satellite (GPS) signals. Reducing risk and improving safety, the technology increases navigational coverage, especially in remote areas beyond radar range. Additionally, ADS-B enables more direct flight plans, thereby saving time, costs, and reducing emissions. This technology enhances situational awareness for Air Traffic Control of aircraft with ADS-B Out capabilities and is mandated by the FAA effective January 2020, followed by EASA in June 2020.

AerTrak kits include all necessary parts and can be installed by AerSale’s technicians at any hangar around the world, typically requiring only three days of ground time. Lead time for ordering AerTrak is currently four weeks and allows operators to avoid potential installation facility backlogs, component shortages, and price premiums as the 2020 compliance deadline nears.

About AerSale

A global aviation leader, AerSale specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul (MRO) services and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. Headquartered in Coral Gables, Florida, AerSale maintains offices and operations in the United States, Europe, and Asia.

For more information, visit our website at www.aersale.com or contact AerSale Media Relations by calling (305) 764-3200 or via e-mail at media.relations@aersale.com.

Follow us on:

LinkedIn | Twitter | Facebook | Instagram

Contacts
AerSale
Lyndelle Nieuwkerk, +1-305-764-3200
media.relations@aersale.com

Permalink : https://www.aetoswire.com/news/easa-approves-aertrak-ads-b-out-system-for-boeing-737-ng-series-aircraft/en

Universal Laser Systems Expands Its Materials Database with 3M and Angstron Materials

SCOTTSDALE, Ariz. -Thursday 25 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Universal Laser Systems (ULS) announces the addition of 3M™ and Angstron materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts.

The 3M and Angstron materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification.

The materials include:

    3M™ 1529 Microporous Rayon Nonwoven Fabric Medical Tape
    3M™ 1776 Polyester Spunlace Nonwoven Fabric Medical Tape
    Angstron Materials AT1500-25 Thermal Foil

Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and development, and prototyping activities.

About Universal Laser Systems, Inc.

Universal Laser Systems, Inc. (ULS) is a global manufacturer of laser material processing solutions, committed to innovation and advancing the application of modern CO2 and fiber laser technology. From the development of laser sources, productivity enhancement technologies, advanced software and beam delivery systems, to an extensive investment in the research of laser materials processing science and applications, ULS provides its customers the most innovative, cost-effective, flexible and scalable laser material processing solutions for today and future needs. For more information, visit www.ulsinc.com.



View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005235/en/

Contacts

Universal Laser Systems, Inc.
James Rabideau, 480-483-1214
jrabideau@ulsinc.com
www.ulsinc.com

Permalink : https://www.aetoswire.com/news/universal-laser-systems-expands-its-materials-database-with-3m-and-angstron-materials/en

Monday, October 29, 2018

Trisymbiotic IP®, a Small Startup, Announces U.S. Patent 10,020,436 Which Surpasses in Facilities Efficiency the Fastest Supercomputers from the U.S. and China

LAREDO, Texas -Thursday 25 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Inventor Matteo Gravina patents three inventions for high performance computing and data center industries. With over 200 GFLOPs per watt claimed by the patent portfolio, this might be one of the greenest patent portfolios on the planet.

The marketplace for data centers has a metric for power efficiency. The power usage effectiveness of 1.0 is the total amount of energy delivered to the servers equal to the total power use by the facility. PUE is the ratio of the total amount of power use by a facility to the energy delivered to the servers and rack equipment. According to the portfolio patent specification's, a negative power usage effectiveness is achievable, in this case, electrical power is extracted at a higher level than what is introduced to power the servers.

    200 Billion Floating Point Operations per Second per Watt
    Negative Power Usage Effectiveness
    Exascale computing at 5 MW
    Space 5.0

At the concept stage, Trisymbiotic IP® has a three patent portfolio held by the inventor Matteo Gravina. A report detailing the inventions, and how to use them is online. Besides the implementation, the intellectual property portfolio entails consequences as well as opportunities. The Trisymbiotic Intellectual Property Portfolio report is downloadable at the website: https://www.trisymbiotic.com/





View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005098/en/

Contacts

Trisymbiotic IP®
Matteo Gravina, 929-800-2398
mgravina@trisymbiotic.com

Permalink : https://www.aetoswire.com/news/trisymbiotic-ipreg-a-small-startup-announces-us-patent-10020436-which-surpasses-in-facilities-efficiency-the-fastest-supercomputers-from-the-us-and-china/en

Kymeta Successfully Demonstrates Hybrid Data Backhaul on Cellular and Satellite Networks

In partnership with Cradlepoint, Inc., TrellisWare Technologies, and CopaSAT, LLC, Redmond-based communications company proved capability of seamless communications near southern U.S. border

REDMOND, Wash. -Thursday 25 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- In September 2018, Kymeta—the communications company making good on the promise of global, mobile connectivity—conducted a series of field trials with United States federal agents to successfully demonstrate the benefits and feasibility of reliable, seamless communications along the southern border of New Mexico. Along with partner CopaSAT, and trial partners Cradlepoint, Inc. and TrellisWare Technologies, Kymeta demonstrated the reliability of its dynamic network capabilities that leveraged both cellular and satellite from a moving platform.

Kymeta successfully demonstrated a complete hybrid network architecture to field agents operating in a communications degraded environment. The Kymeta terminal provided on-the-move connectivity to SES satellites which was blended with terrestrial LTE networks using a Cradlepoint software defined wide-area-network (SD-WAN) router. Access to this network was extended to agents using TrellisWare mobile ad-hoc mesh net (MANET) radios. Kymeta’s hybridization model combines satellite and cellular networks for enhanced performance and allows for dynamic traffic management between networks enabling best-cost data routing and other software defined features. Agents used existing communications equipment as-is, with no modifications or satellite expertise required to access the network. Smart devices, laptops, unmanned aerial systems (UAS), cameras, and other communications solutions stayed connected from a moving vehicle with no disruption in service or network quality.

“Traditionally, mobile satellite solutions come in the form of very small aperture terminals (VSAT) mounted on specially designed communications vehicles or deployable field kits that only provide communications when stationary and require a technician to setup and point the antenna,” said Scott Tatum, Director, Complex Solutions, CopaSAT. “The technology brought by Kymeta demonstrated that reliable satellite communications can exist on virtually any mobile platform, on the move, and with little to no operator training or involvement.”

The architecture leveraged an SD-WAN topology to combine satellite and cellular network technologies. Using SD-WAN is critical as it enables dynamic backhaul routing using the best backhaul connections available. In a dense urban environment with modern infrastructure, LTE might be the best path. However, in remote operational areas satellite is likely best. When both solutions represent beneficial backhaul pathways, the SD-WAN is leveraged to intelligently route data and shape traffic flow. Mission critical information can be delivered via multiple pathways for redundancy, where high-bandwidth traffic, such as file sharing, could be routed to a separate connection. The SD-WAN makes the best decision on how to route data in a dynamic and changing environment so that operators can focus on the task at hand.

“The combination of these devices and solutions enabled secure and seamless communications from operators in a field environment to other operators and commanders distributed across the country,” said Ben Posthuma, Senior Solutions Engineer, Kymeta. “The system automatically and dynamically switched between cellular and satellite to find the best connection quality. The agents didn’t have to tell the system to switch, it just happened. All the users had to do was connect to the Wi-Fi in their vehicles, and the system did the rest without additional intervention.”

In addition, the system provides the added benefit of working with existing communications equipment.

“Kymeta eliminates communications challenges in the field by providing low-profile, mobile SATCOM solutions that can deliver mission-critical information regardless of location,” said Posthuma. “The antenna works with existing communications tools exactly how they were purchased to be used and trained to be used. The hybridized solution allows for leveraging existing tools without anyone having to become a SATCOM expert.”

The results of the trial will allow Kymeta to move forward in enabling hybridized services to organizations around the world, giving them access to full situational awareness in the field, whether stationary or on the move.

About Kymeta

The world’s demand for ubiquitous mobile connectivity is irrefutable. A global, mobile network is the answer to connecting people and places that have never been connected before.

Kymeta is making seamless, always-connected mobile communications possible with a unique hybrid approach that enables satellite and cellular networks to deliver a single, global, mobile network. End-to-end mobile communications are delivered with Kymeta KĀLO™ connectivity services, and the world’s first and only electronically-steered, flat-panel satellite terminal that goes places traditional satellite dishes cannot. The Kymeta KyWay™ terminal makes high-throughput, mobile communications possible in cars, trains, buses, trucks, boats, and much more.

If it moves, Kymeta keeps it connected.

For more information, visit kymetacorp.com and KALO.net.





View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005232/en/

Contacts

Business Inquiries for Kymeta:
Kymeta Corporation
Sam Christensen
Marketing
+1 425.658.8703
schristensen@kymetacorp.com
or
Media Inquiries for Kymeta:
The Summit Group
Amy Oliver
PR/Content Manager
+1 801.990.1185
aoliver@summitslc.com

Permalink : https://www.aetoswire.com/news/kymeta-successfully-demonstrates-hybrid-data-backhaul-on-cellular-and-satellite-networks/en

Immervision Files Complaints for Patent Infringement against LG Electronics over 5 Smartphones with Wide-Angle Cameras

The complaints filed by Immervision accuse LG models LG G6, LG V20, LG V30, LG G7 and LG V35 of infringing Immervision’s U.S. Patent No. 6,844,990

MONTREAL-Thursday 25 October 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- Immervision, a Montreal-based developer of patented, wide-angle optic and imaging technology, filed patent infringement lawsuits against LG Electronics and LG Electronics U.S.A., Inc. in the Unites States District Court for the District of Delaware. The patent is generally related to wide-angle imaging technology in the areas of lens design and software-based image processing.

Immervision holds multiple patent families in imaging technology and has successfully enforced its patents in the past.

Pascale Nini, Immervision President and CEO, said “As the experts in wide-angle imaging technology, our purpose is to enable intelligent vision for any industry and application, and make Immervision intellectual property available to all and at mutually beneficial terms. Immervision has licensed its technology to premium smartphone brands such as Motorola, Acer, and Crosscall. Wide-angle imaging is a requirement for the latest devices, and other license deals with major Chinese OEMs are expected soon.”

About Immervision

Immervision enables intelligent vision in any device. We design wide-angle lenses with augmented resolution to see more, and AI-ready image processing to see smarter. Our technology is for smart professional applications, consumer devices, automotive, robotics, medical, and other industries. Vision is key to understanding and securing the environment and to entertaining and informing the world. Immervision continuously adapts its technology and licenses it to component manufacturers, OEMs, and ODMs in the imaging eco-system.

Contacts
Immervision
Angus Mackay, +1 514 985 4007 ext. 3037
angus.mackay@immervision.com
www.immervision.com

Permalink : https://www.aetoswire.com/news/immervision-files-complaints-for-patent-infringement-against-lg-electronics-over-5-smartphones-with-wide-angle-cameras/en

PotNetwork Holdings, Inc. Announces New CEO: Kevin Hagen, and Other Changes

Dr. Richard Goulding to Assume Leadership Role as Chief Medical Officer, Focused on Diamond CBD Product Development and Clinical Trials

FORT LAUDERDALE, Fla.-Friday 26 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- PotNetwork Holdings, Inc. (OTC Pink: POTN) (the “Company”) announced today that Kevin Hagen, President of its subsidiary, First Capital Venture Co., owner of Diamond CBD, Inc., has been appointed as new Chief Executive Officer effective immediately.

Former CEO, Dr. Richard Goulding, assumes the new role of Chief Medical Officer, spearheading new product development and clinical testing of new proprietary products. Dr. Goulding will devote his time solely to this role, terminating any involvement with other entrepreneurial initiatives and affiliations, private or public, in the CBD industry. Dr. Goulding will focus on product development, in an effort to expand and enhance the Company’s offerings.

Kevin Hagen, new CEO, stated, “We want to thank Dr. Goulding for meeting the considerable demands in the past of being both our CEO, and Chairman of our medical advisory board. We are certain that as Chief Medical Officer, he will assist us in navigating the complexities we face with our new hemp-derived CBD product initiatives, as he works with our other advisory doctors, scientists and specialist legal counsel.” He added, “Since early 2017 we have been building our brand, consumer base, and product line. As we close 2018 and enter 2019, we plan to become a more robust company, with solid distribution and sales, upon which we can continue to build more brands and penetrate more markets. The achievement of long-term shareholder value is our goal, not short-term stock gains. We have our eyes fixed on getting to NASDAQ in the years ahead, which is a worthy goal for any early stage public company.”

About Diamond CBD, Inc.: Diamond CBD focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD’s team consists of hemp industry pioneers and natural product experts, chemists, doctors and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a robust selection considered among the most powerful natural CBD oils, tinctures, edibles, and vape liquids found anywhere. For more information, please visit its website at www.DiamondCBD.com.

About PotNetwork Holdings, Inc.: PotNetwork Holdings, Inc. (OTC Pink: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils.

Safe Harbor: This press release contains Forward-Looking Statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
PotNetwork Holdings, Inc.
Marisol Elwell, 1-800-915-3060
investor@PotNetworkHolding.com




Permalink : https://www.aetoswire.com/news/potnetwork-holdings-inc-announces-new-ceo-kevin-hagen-and-other-changes/en

Nashwa Al Ruwaini First Emirati Woman to Win Mother Teresa Memorial Award for Social

Abu Dhabi, United Arab Emirates-Wednesday 24 October 2018 [ AETOS Wire ]

Nashwa Al Ruwaini, the Emirati entrepreneur was one of the winners of the Mother Teresa Memorial Award for Social Justice 2018. She was awarded for all her philanthropic efforts in revolutionizing the image of women in the Middle East as well as all her charitable activities that she has undertaken to improve the lives of women and children through her humanitarian organization-the Nashwa Foundation.

Al Ruwaini was granted the award in Mumbai India at a ceremony organized by the Harmony Foundation following a conference with the theme of ‘Protect Her Empower Her’ focused on the empowerment of the girl child where Al Ruwaini spoke about the role of lobbying for laws, society and technology in protecting and empowering young women-a cause Al Ruwaini is very dedicated to. She received the award from the great grandson of the legendary Mahatma Gandhi, Mr. Shri Tushar Arun Gandi in the presence of His Excellency Mohamed Al Jalah Al Teneiji, the UAE Consul General in Mumbai and is the first Emirati woman to win this Award.

On the occasion, Nashwa Al Ruwaini said, “It is such a great honour to win this accolade that I am extremely proud of and that is very dear to my heart. This is especially the case as Mother Teresa is one of my favourite role models who I aspire to be just as charitable and because it serves as a reminder that I need to continue my philanthropic work which I find to be just as important as my professional career. I believe that it is my role and purpose to always give back to the community, especially to women and young girls so that they can lead healthy lives and not be subjected to any form of oppression or injustice and I will continue to work towards this goal especially in the Middle East.”

She also added that under the wise guidance of the UAE leadership, especially Her Highness Sheikha Fatima bint Mubarak also known as the ‘Mother of the Emirates,’ women are provided with all the necessary resources and systems allowing them to succeed, fulfil their goals and be an integral and significant part of the society and that she wished this was the case for all women and young girls in the region.

Former winners of the Mother Teresa Award for Social Justice include in 2016 His Highness Sheikh Abdullah bin Zayed bin Sultan Al Nahyan, Minister of Foreign Affairs and International Cooperation in the United Arab Emirates, Mahatir Mohamed, the Dalai Lama and Nobel Laureate Malala Yousafzai.

This year other awardees alongside Nashwa Al Ruwaini include the winners of the Nobel Peace Prize 2018 Nadia Murad, a Yazidi survivor and Denis Mukwege, a gynecologist who provides medical, legal, psychological and economic support to survivors of rape.

Contacts
Reham Barakat

Pyramedia

reham.barakat@pyramedia.biz

00971508228604

Permalink : https://www.aetoswire.com/news/nashwa-al-ruwaini-first-emirati-woman-to-win-mother-teresa-memorial-award-for-social-justice/en

Sunday, October 28, 2018

Mentice Appoints New Member to its Board of Directors

GOTHENBURG, Sweden -Wednesday 24 October 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Mentice, the world leading provider of endovascular performance solutions, announced today the appointment of a new independent member to its Board of Directors.

David J. Ballard, M.D., M.S.P.H., Ph.D., F.A.C.P., is a global healthcare executive with proven expertise in improving healthcare value and organizational financial performance while providing international thought leadership. Dr. Ballard was recognized by Becker’s as one of the top 50 experts leading the field of Patient Safety in 2015, 2016, 2017 and 2018 and is the past President of the International Society for Quality in Healthcare. Widely recognized as a global scholar in healthcare quality and value, his two books on healthcare quality leadership received Shingo Awards for their contributions to operational excellence.

“I am excited to join the Mentice board of directors,” says David Ballard, “I am engaging this role because I believe that Mentice technology and solutions can be transformative in our global quest to reduce harm to patients and to make healthcare more affordable.”

Dr. Ballard has served as Chief Quality Officer of Baylor Scott & White Health, the largest healthcare system in Texas (1999-2018). Previously, David served in leadership roles at Emory University (1994-1999), University of Virginia (1991-1994) and Mayo Clinic (1986-1991) after completing degrees in economics, epidemiology and medicine at the University of North Carolina where he was a John Motley Morehead Scholar and training in internal medicine at the Mayo Clinic where he now serves as Healthcare Policy Section Editor for the Mayo Clinic Proceedings.

“It is an honor to have Dr Ballard join our board,” says Lonnie Howell, Chairman of Mentice. “Dr Ballard’s experience from executive positions in large health systems and his global leadership in patient safety will help us drive our expansion with use of our technology for the continuous practice.” Mr. Howell continues, “Our solutions are the established standard for the world’s medical device manufacturers as well as academic medical centers across the world; our next frontier is leveraging the potential of clinical simulation in the continuous practice of improvement in healthcare to reduce harm and the costs of care.”

Mentice is the world leader in virtual reality-based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and preprocedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. For more information about Mentice, visit www.mentice.com.



View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005084/en/

Contacts
Mentice
Hiral Chavda
Marketing Communications Manager
+46 (0) 31 339 94 94
hiral.chavda@mentice.com


Permalink : https://www.aetoswire.com/news/mentice-appoints-new-member-to-its-board-of-directors/en


Digital Transformation Takes Pharma Beyond the Pill



Collaborative deployment of digital enablers such as artificial intelligence, IoT, and blockchain aid in shift toward value-based care

Dubai, United Arab Emirates, -Sunday 28 October 2018 [ AETOS Wire ]

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google—pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge technologies to build digital convergence across the pharmaceutical value chain.

"Digital transformation in pharmaceuticals is leading to tectonic shifts in the way companies and stakeholders traditionally conduct business by introducing novel business and data monetization models and investment opportunities,” said Neelotpal Goswami, Senior Industry Analyst with Frost &amp; Sullivan’s global Transformational Healthgroup. “The move toward a value-based care model is driving the need for better drug adherence and efficacy, which in turn is driving the need to optimize performance.”

Frost &amp; Sullivan’s recent intelligence, Digital Transformation In Pharmaceuticals Industry, 2018, Companies-To-Action, provides a detailed analysis of the key digital enablers, such as artificial intelligence, big data, internet of things (IoT), and blockchain that are bringing digital continuity across smart R&amp;D, flexible manufacturing, connected patients, and digital pharmacy. It also includes key market participants that are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.

For further information on this analysis, please click here.

Disruptive innovations driving growth within the pharmaceuticals industry include:

Application of AI and big-data analytics, by companies such as Benevolent AI and Exscientia, to crunch through structured and unstructured data is expected to improve drug discovery success rates.
Virtualization of clinical trials, by Science 37 and Transparency Life Science, by using cloud and mobile-based modelstransforming trials methodologies and reducing timelines and errors.
Application of IoT models and blockchain-based methodologies in operations and supply chains will reduce inefficiencies and improve functional visibility, as provided by Elemental Machines and iSolve.
Novel e-commerce, digitally-enabled pharmacies such as PillPack, and distribution models will reduce costs and improve access to novel treatments;
Improved patient connect using AI-enabled patient focused mobile apps as well as use of big-data analytics to improve patient care and drug adherence as provided by companies such as Proteus Digital Health and uMotif
Using mergers and acquisitions (M&amp;A) to build life science digital capabilities, for example, Roche’s acquisition of Flatiron.
“We expect digitalization to continue driving the evolution across the pharmaceutical value chain,” said Goswami. “To avail themselves of the opportunities for growth, vendors will need to rely on strategic commercial engagements and R&amp;D alliances, along with developing proprietary and patented technology as per patient needs.”

Digital Transformation In Pharmaceuticals Industry, 2018, Companies-To-Action, is part of Frost &amp; Sullivan’s Transformational Health Growth Partnership Service program.

About Frost &amp; Sullivan

For over five decades, Frost &amp; Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion

Digital Transformation In Pharmaceuticals Industry, 2018, Companies-To-Action

MDE1-52



Twitter: @Frost_Sullivan &amp; @Frost_MENASA
Facebook: http://www.facebook.com/frostandsullivan
LinkedIn: https://www.linkedin.com/showcase/frost-&amp;-sullivan-%E2%80%93-middle-east-north-africa-south-asia/ 

Contacts
Anita Chandhoke
Corporate Communications - MEA
P: +91 80 67028020
E: achandhoke@frost.com

http://ww2.frost.com

Permalink : https://www.aetoswire.com/news/digital-transformation-takes-pharma-beyond-the-pill/en

Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION




OSAKA, Japan-Sunday 28 October 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today issued the following statement with regard to its discussions with the European Commission (“EC”) as part of its Phase 1 review of the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”):

Takeda confirms that it is in discussions with the EC in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda’s marketed product Entyvio (vedolizumab) and Shire’s pipeline compound SHP647, which is currently in Phase III clinical trials, and has proposed a remedy of a potential divestment of SHP647 and certain associated rights.

The company remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda’s diverse specialty gastrointestinal portfolio.

Takeda confirms that there are no discussions with the EC regarding any other marketed products or assets in the pipeline.

Takeda does not anticipate that its discussions with the EC will result in a delay to its previously announced timetable for completion of the transaction. A further announcement will be made as appropriate.

The Acquisition remains subject to certain other conditions, including receipt of the remaining regulatory clearances and approval by the shareholders of both companies.

About Entyvio® (vedolizumab)

Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.14 These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.

Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist. Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date. 6

Therapeutic Indications

Ulcerative colitis

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Crohn’s disease

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Important Safety Information

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Special warnings and special precautions for use

Vedolizumab should be administered by a healthcare professional equipped to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering vedolizumab. Observe all patients during infusion and until the infusion is complete.

Infusion-related reactions

In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity. If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of vedolizumab must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines). If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated (e.g., epinephrine and antihistamines). Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks.

Infections

Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier. Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Before starting treatment with vedolizumab, screening for tuberculosis may be considered according to local practice. Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the α4β7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect on the gut. Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known. Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur. If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months.

Malignancies

The risk of malignancy is increased in patients with ulcerative colitis and Crohn’s disease. Immunomodulatory medicinal products may increase the risk of malignancy.

Prior and concurrent use of biological products

No vedolizumab clinical trial data are available for patients previously treated with natalizumab. Caution should be exercised when considering the use of vedolizumab in these patients. No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of vedolizumab in such patients is not recommended.

Vaccinations

Prior to initiating treatment with vedolizumab all patients should be brought up to date with all recommended immunizations. Patients receiving vedolizumab may receive non-live vaccines (e.g., subunit or inactivated vaccines) and may receive live vaccines only if the benefits outweigh the risks.

Adverse reactions include: nasopharyngitis, headache, arthralgia, upper respiratory tract infection, bronchitis, influenza, sinusitis, cough, oropharyngeal pain, nausea, rash, pruritus, back pain, pain in extremities, pyrexia, and fatigue.

Please consult with your local regulatory agency for approved labeling in your country.

For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO®.7

For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO®.

Takeda’s Commitment to Gastroenterology

Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.

Important Notice

This announcement is not intended to, and does not, constitute, represent or form part of any offer, invitation or solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions. Any failure to comply with such restrictions may constitute a violation of the securities laws or regulations of any such relevant jurisdiction.

Publication on Website

In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on October 29, 2018. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

1 Entyvio® Summary of Product Characteristics. March 2018.
2 Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.
3 Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97 110.
4 Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its roles in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14:1298 1312.
5 Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437-1444.
6 Takeda. 2018. Data on file.
7 Entyvio (vedolizumab) Prescribing Information. February 2018.





Contacts

Takeda (Investor Relations)
Takashi Okubo
takeda.ir.contact@takeda.com
+81 3 3278 2306
or
Takeda (Media – inside Japan)
Tsuyoshi Tada
Tsuyoshi.Tada@takeda.com
+1 617 551 2933
or
Kazumi Kobayashi
Kazumi.Kobayashi@takeda.com
+81 3 3278 2095
or
Takeda (Media – outside Japan)
Elissa Johnsen
Elissa.Johnsen@takeda.com
+1 312 285 3203




Permalink : https://www.aetoswire.com/news/takeda-comments-on-ongoing-phase-1-review-by-the-european-commission-of-the-proposed-acquisition-of-shire-plc/en

RTA unveils finalists of Dubai World Challenge for Self-Driving Transport


Dubai, United Arab Emirates-Sunday 28 October 2018 [ AETOS Wire ]

HE Mattar Al Tayer, Director-General and Chairman of the Board of Executive Directors of Dubai Roads and Transport Authority (RTA), announced that the participation in the Dubai World Challenge for Self-Driving Transport had exceeded the target by 30%, by the end of registration phase. Al Tayer made this statement during a press conference held to announce the finalists of the Challenge.

Companies, universities, colleges and institutions submitted applications globally. Attendees of the event included Dr. Arif Al Hammadi Executive Vice President of Khalifa University, Ms. Laila Faridoon, Chairperson of the Organising Committee of the Dubai World Congress for Self-Driving Transport; Dr. Steve Shladover, the International Jury Head of Dubai World Challenge for Self-Driving Transport; and Adel Shakri, Head of the Dubai World Challenge for Self-Driving Transport Committee.

The Leaders Category finalists included: Navya and EasyMile from France, Drive.ai from the USA, Westfield from the UK, Baidu from China, and 2getthere from the Netherland.

The list of start-ups finalists included: Sensible from Finland, Derq from the UAE, and IAuto from Taiwan.

As for the local universities, announced finalists were: Dubai University, UAE University, Al Ain University of Science and Technology, and Abu Dhabi University. Amongst the international universities, Friee Berlin University in Germany, CMU in the US, Intelligent Systems Lab at Universidad Carlos lll de Madrid in Spain, and UTS in Australia represent the finalists of this category.

 “The Challenge award amounts to more than US$5 million; US$3 million will be allocated to leader’s category, US$1.5m to start-ups category, and US$600,000 to local and foreign universities (US$300,000 each). A team of international experts in the field of smart mobility will assess the finalists by several technical criteria,” said Al Tayer.

“The challenge encourages the participants to cope with the existing challenges of the First /Last Mile, traffic congestions and the drop in the public transport ridership. Driverless transport has become a key pillar of RTA’s strategy, and we are making every endeavour to make it a reality in Dubai,” he added.

Finalists will be subjected to intensive tests in Dubai in 2019, and an international jury panel will review all submissions to select the winners of the inaugural edition of the Challenge. Winners will be honoured during the first edition of the Dubai World Conference for Self-Driving Transport scheduled to be held in October 2019.

Al Tayer also praised the Dubai World Challenge for Self-Driving Transport partners: Telecommunications Regulatory Authority, Union Properties, Meraas, Dubai Silicon Oasis and Dubai Future Foundation

Challenge Standards

The Finalists were assessed by several parameters including: The credibility, vision, skills and relevant experiences of the entity. Nominees will then be judged in their respective categories according to their performance in tests conducted as per the following standards:

    Technical ability and experience: Vehicle manufacturing, flexibility, battery technology, and the command & control system
    Business aspect: Operability, added value, and relevance to the needs of Dubai and the UAE.
    Operation and service: Innovative solutions, operation method, the ability to run services and working hours.

The Challenge encompasses a series of tests related to:

    Durability and reliability
    Ability to drive under traffic conditions simulating the reality
    Power efficiency and environmental compatibility
    Electronic safety and security
    User’s experience

Contacts

Roads and Transport Authority (RTA)

Maryam Al Balooshi, Manager, Media Communication

Marketing and Corporate Communication Department

Tel: +97142902699